Cucurbitacin B degrades EGFR and downregulates the CIP2A/PP2A/AKT axis, inhibiting growth and invasion of gefitinib-resistant NSCLC and reducing xenograft tumor volume [43]. This evidence concerns the gene AKT1 and neoplasm.